【重磅】布地奈德缓释胶囊治疗IgA肾病取得重大突破

IgA nephropathy (IgAN) is one of the primary glomerular diseases with the highest incidence rate worldwide and has a poor prognosis. About 15%-40% of patients will progress to end-stage renal disease (ESRD) 10-20 years after the onset of the disease, and eventually need to rely on renal replacement therapy, which brings a heavy burden to society and families. The pathogenesis of IgAN is related to multiple factors such as genetics, environment, and immune disorders. Upper respiratory tract infections and intestinal infections can often induce or aggravate IgAN. Abnormal activation of the mucosal immune system, mainly tonsils and intestinal mucosa, plays an important role in the pathogenesis of IgAN. A recent study confirmed a major breakthrough in the treatment of IgA nephropathy.

Professor Bengt C Fellström from Uppsala University in Sweden conducted a clinical study on targeted therapy for IgA nephropathy (IgAN). The results of the study have been published in The Lancet. This is a randomized, double-blind controlled trial, currently in phase 2b. Its purpose is to evaluate the efficacy and safety of budesonide sustained-release capsules in the treatment of IgAN.

This drug can be targeted for release in the terminal ileum and is highly aggregated, preventing the activation of B lymphocytes to produce IgA. Only 10% of the budesonide of this drug enters the systemic circulation. In the trial, 150 patients with primary IgAN were randomly divided into 3 groups, who were given budesonide sustained-release capsules 8 mg/d, 16 mg/d, and placebo respectively, with basic RAS blocking treatment. After 9 months of treatment, the urinary protein and creatinine of patients in the budesonide group (16 mg/d, 8 mg/d) decreased by 24.4% (27.3%, 21.5%) compared with the baseline. , while the urinary protein and creatinine in the placebo group only decreased by 0.74% compared with the baseline, and there was no significant difference in the incidence of adverse events among the three groups. Researchers believe that budesonide capsules combined with RASB can effectively reduce urinary protein in patients with IgAN.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.